Amgen psoriasis candidate bests J&J's Stelara; FDA slams Sciecure insomnia drug sales materials;

> Amgen's ($AMGN) psoriasis drug brodalumab beat Johnson & Johnson's ($JNJ) Stelara at clearing patients' skin in a late-stage study, in the latest round of data for a soon-to-be-upended psoriasis market. Report

> The FDA's pharma marketing police slammed Sciecure Pharma for a lack of fair balance in a sales aid for its insomnia drug Doral. Report

> South Carolina-based Afaxys Pharmaceuticals says its emergency contraceptive, ella, is now available nationwide in the U.S.; the company is particularly focusing on public health providers, urgent centers, ERs and student health centers. Release

> The U.K. drugmaker BTG said it has finally launched its varicose vein treatment Varithena in the U.S., 18 years after it bought the technology. Release

And Finally... Servier is gambling up to $1B on Intarcia's late-stage drug-emitting diabetes device. Report

Suggested Articles

A month after the FDA approved it, Esperion's Nexletol showed it can lower cholesterol regardless of statin and ezitimibe treatment.

Bluebird said it doesn't expect to complete a U.S. application for the gene therapy until mid-2021 amid COVID-19 and a lack of agreement with the FDA.

W2O Group and California Life Sciences' new data-driven platform tracks top COVID-19 news and conversations in the life science industry.